Iovance Biotherapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). 

CEO
Frederick G. Vogt
CEOFrederick G. Vogt
Employees
975
Employees975
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2007
Founded2007
Employees
975
Employees975

IOVA Key Statistics

Market cap
6.41B
Market cap6.41B
Price-Earnings ratio
-19.71
Price-Earnings ratio-19.71
Dividend yield
—
Dividend yield—
Average volume
21.73M
Average volume21.73M
High today
$14.41
High today$14.41
Low today
$13.71
Low today$13.71
Open price
$14.05
Open price$14.05
Volume
11.73M
Volume11.73M
52 Week high
$15.30
52 Week high$15.30
52 Week low
$1.76
52 Week low$1.76

Stock Snapshot

With a market cap of 6.41B, Iovance Biotherapeutics(IOVA) trades at $14.17. The stock has a price-to-earnings ratio of -19.71.

On 2026-10-05, Iovance Biotherapeutics(IOVA) stock moved within a range of $13.71 to $14.41. With shares now at $14.17, the stock is trading +3.4% above its intraday low and -1.6% below the session's peak.

Trading activity shows a volume of 11.73M, compared to an average daily volume of 21.73M.

Over the past 52 weeks, Iovance Biotherapeutics(IOVA) stock has traded between a high of $15.30 and a low of $1.76.

Over the past 52 weeks, Iovance Biotherapeutics(IOVA) stock has traded between a high of $15.30 and a low of $1.76.

IOVA News

Benzinga 9h
Top 3 Health Care Stocks That May Collapse In Q4 - Benzinga

...

Top 3 Health Care Stocks That May Collapse In Q4 - Benzinga
Simply Wall St 4d
What’s Behind Iovance Biotherapeutics Latest Move?

Iovance Biotherapeutics (IOVA) just raised its 2026 revenue outlook to a range of US$410 million to US$420 million, citing strong U.S. demand for Amtagvi and Pr...

What’s Behind Iovance Biotherapeutics Latest Move?
TipRanks 4d
Iovance Biotherapeutics appoints Berkowitz as CMO

Iovance Biotherapeutics (IOVA) announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, CMO, effective September 30, 2026. Berkowitz...

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

More IOVA News

Simply Wall St 5d
Why Iovance Biotherapeutics Stock Is In Focus After Revenue Guidance Raise

Iovance Biotherapeutics recently lifted its full year 2026 revenue guidance to US$410 million to US$420 million, citing strong U.S. demand for its Amtagvi and P...

Why Iovance Biotherapeutics Stock Is In Focus After Revenue Guidance Raise
Zacks 5d
Iovance Biotherapeutics Surges 31.5%: Is This an Indication of Further Gains?

Iovance Biotherapeutics (IOVA Quick QuoteIOVA - Free Report) shares ended the last trading session 31.5% higher at $14.45. The jump came on an impressive...

Iovance Biotherapeutics Surges 31.5%: Is This an Indication of Further Gains?

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.